Loading the company…
Loading the company…
㈜일진에스앤티
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2007. Industry: Holding & Financial Services. Revenue for 2025 was ₩0. It has 7 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2023-08-11 · newest first
본 발명은 신규한 벤조[d][1,2,3]트리아진 유도체 및 이의 용도에 관한 것으로, 상기 신규한 벤조[d][1,2,3]트리아진 유도체는 우수한 SOS1의 GTP 치환 억제 활성을 갖는 것으로 SOS1 매개 질환 및 암과 같은 질환의 예방 및 치료용 약학 조성물로 유용하게 사용가능하다.
본 발명은 세포 내 존재하는 유비퀴틴-프로테아좀 시스템을 활용하는 키메라성 분해 유도 화합물(PROTAC) 및 γ-부티로베타인 하이드록실라아제 1(BBOX1)과 관련된 질환 특히 암의 치료 또는 예방에 유용한 이들 화합물의 의약 용도에 관한 것이다. 본 발명의 신규한 PROTAC 화합물은 BBOX1 분해작용 효과를 가지고 있으므로 암의 예방 또는 치료용 조성물로 유용하게 사용가능하다.
본 발명은 2-헤테로아릴아미노 아세트산 유도체 또는 2-벤조일아미노 아세트산 유도체 화합물 및 γ-부티로베타인 하이드록실라아제 1(BBOX1)과 관련된 질환 특히 암의 치료 또는 예방에 유용한 이들 화합물의 의약 용도에 관한 것이다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Selling, general and administrative expenses | 1.8 | 2.0 |
| Operating income (loss) | (1.8) | (2.0) |
| Non-operating income | 3.0 | 7.2 |
| Other gains | 0.0 | 0.0 |
| Finance income | 1.4 | 0.2 |
| Other | 1.6 | 6.9 |
| Non-operating expenses | 4.0 | 0.5 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.3 | — |
| Other | 3.7 | 0.5 |
| Profit (loss) before tax | (2.8) | 4.7 |
| Income tax expense | (1.1) | 0.3 |
| Net income (loss) | (1.8) | 4.4 |
Revenue —.
Operating margin —.
Net income ₩4.4bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.